Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT)

A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma

A. Donfrancesco, G. Deb, C. Dominici, A. Angioni, M. Caniglia, L. De Sio, P. Fidani, A. Amici, L. Helson

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Thirteen patients with Stage III (3 patients) or Stage IV (10 patients) neuroblastoma were treated with a new iron chelation-cytotoxic therapy regimen. Deferoxamine given for five consecutive days followed by 3 days of cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT) caused moderate to severe myelotoxicity. In 39 courses there were four episodes of sepsis; platelet and packed red blood cell transfusions were required in 72% and 82% of courses, respectively. Mild nausea and vomiting occurred in 52% of courses. Objective responses after two courses were observed in 12 of 13 patients. Three of four partial responses were achieved in previously treated relapsed patients, and seven of eight complete responses (four of which were surgically documented) were achieved in previously untreated patients. This cytoreduction regimen appears to be an improvement over other initial induction regimens and may be worth testing in larger populations.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number4
Publication statusPublished - 1992

Fingerprint

Thiotepa
Deferoxamine
Carboplatin
Etoposide
Neuroblastoma
Cyclophosphamide
Drug Therapy
Chelation Therapy
Erythrocyte Transfusion
Nausea
Vomiting
Sepsis
Blood Platelets
Iron
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT) : A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. / Donfrancesco, A.; Deb, G.; Dominici, C.; Angioni, A.; Caniglia, M.; De Sio, L.; Fidani, P.; Amici, A.; Helson, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 4, 1992, p. 319-322.

Research output: Contribution to journalArticle

@article{d0afeaf8994a4ff9aebe642c35caf0d8,
title = "Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma",
abstract = "Thirteen patients with Stage III (3 patients) or Stage IV (10 patients) neuroblastoma were treated with a new iron chelation-cytotoxic therapy regimen. Deferoxamine given for five consecutive days followed by 3 days of cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT) caused moderate to severe myelotoxicity. In 39 courses there were four episodes of sepsis; platelet and packed red blood cell transfusions were required in 72{\%} and 82{\%} of courses, respectively. Mild nausea and vomiting occurred in 52{\%} of courses. Objective responses after two courses were observed in 12 of 13 patients. Three of four partial responses were achieved in previously treated relapsed patients, and seven of eight complete responses (four of which were surgically documented) were achieved in previously untreated patients. This cytoreduction regimen appears to be an improvement over other initial induction regimens and may be worth testing in larger populations.",
author = "A. Donfrancesco and G. Deb and C. Dominici and A. Angioni and M. Caniglia and {De Sio}, L. and P. Fidani and A. Amici and L. Helson",
year = "1992",
language = "English",
volume = "15",
pages = "319--322",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D- CECaT)

T2 - A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma

AU - Donfrancesco, A.

AU - Deb, G.

AU - Dominici, C.

AU - Angioni, A.

AU - Caniglia, M.

AU - De Sio, L.

AU - Fidani, P.

AU - Amici, A.

AU - Helson, L.

PY - 1992

Y1 - 1992

N2 - Thirteen patients with Stage III (3 patients) or Stage IV (10 patients) neuroblastoma were treated with a new iron chelation-cytotoxic therapy regimen. Deferoxamine given for five consecutive days followed by 3 days of cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT) caused moderate to severe myelotoxicity. In 39 courses there were four episodes of sepsis; platelet and packed red blood cell transfusions were required in 72% and 82% of courses, respectively. Mild nausea and vomiting occurred in 52% of courses. Objective responses after two courses were observed in 12 of 13 patients. Three of four partial responses were achieved in previously treated relapsed patients, and seven of eight complete responses (four of which were surgically documented) were achieved in previously untreated patients. This cytoreduction regimen appears to be an improvement over other initial induction regimens and may be worth testing in larger populations.

AB - Thirteen patients with Stage III (3 patients) or Stage IV (10 patients) neuroblastoma were treated with a new iron chelation-cytotoxic therapy regimen. Deferoxamine given for five consecutive days followed by 3 days of cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT) caused moderate to severe myelotoxicity. In 39 courses there were four episodes of sepsis; platelet and packed red blood cell transfusions were required in 72% and 82% of courses, respectively. Mild nausea and vomiting occurred in 52% of courses. Objective responses after two courses were observed in 12 of 13 patients. Three of four partial responses were achieved in previously treated relapsed patients, and seven of eight complete responses (four of which were surgically documented) were achieved in previously untreated patients. This cytoreduction regimen appears to be an improvement over other initial induction regimens and may be worth testing in larger populations.

UR - http://www.scopus.com/inward/record.url?scp=0026683009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026683009&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 319

EP - 322

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -